Wanting T. Qiang
Shanghai, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 25 publications
Extracellular Ubiquitin Drives M2 Macrophage Polarization in Multiple Myeloma Through JAK1/STAT3-mediated Transcriptional Activation of CXCR4.
Journal: Journal of cellular biochemistry
Published: May 30, 2025
GPRC5D-targeted CAR T-cell therapy (CT071) in patients with relapsed or refractory multiple myeloma: a first-in-human, single-centre, single-arm, phase 1 trial.
Journal: The Lancet. Haematology
Published: March 15, 2025
Lowering the Selinexor Dose within the Pomalidomide and Dexamethasone Combination Regimen Elicits Fewer Side Effects While Comparable Efficacy Against Relapsed/Refractory Multiple Myeloma.
Journal: OncoTargets and therapy
Published: January 13, 2025
BCMA chimeric antigen receptor T cells therapy re-treatment of a patient with recurrent/refractory IgD multiple myeloma: A case report and literature review
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: December 02, 2024
Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients.
Journal: BMC medical genomics
Published: October 27, 2024
B-Cell Maturation Antigen/CD19 Dual-Targeting Immunotherapy in Newly Diagnosed Multiple Myeloma.
Journal: JAMA oncology
Published: July 25, 2024
Analysis of efficacy and safety of BCMA chimeric antigen receptor T cells in the treatment of 5 patients with recurrent/refractory IgD multiple myeloma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 19, 2024
A 5-Year Follow-up Clinical Study of the B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy HDS269B in Patients with Relapsed or Refractory Multiple Myeloma.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: February 04, 2024
An open-label, prospective trial to evaluate the efficacy and safety of ixazomib in combination with cyclophosphamide and dexamethasone in patients with newly diagnosed POEMS syndrome.
Journal: British journal of haematology
Published: January 01, 2024
Elevated serum levels of soluble B-cell maturation antigen as a prognostic biomarker for multiple myeloma.
Journal: Clinical and experimental immunology
Published: October 04, 2023
The efficacy and safety analysis of pomalidomide in the treatment of relapsed/refractory multiple myeloma
Journal: Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
Published: March 29, 2023
Last Updated: 09/26/2026